Business Context and Reporting Period
This Form 8-K was filed by Greatbatch, Inc. on June 17, 2014. The report details a regulatory milestone achieved by the Company regarding its medical device division.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance data.
Material Changes
On June 17, 2014, Greatbatch, Inc. received the CE Mark from the European Notified Body, TÜV SÜD America, for its Algovita product (formerly Algostim). Algovita is a Spinal Cord Stimulation System (SCS) designed to treat chronic intractable pain of the trunk and/or limbs.
Outlook and Management Commentary
Management views this approval as a strategic milestone in the Company's evolution to develop complete medical device systems. The goal is to enhance the growth and profitability profile of the Company. This strategy is facilitated through the subsidiary, QiG Group, leveraging Greatbatch's intellectual property and discrete technologies.
Investor Verification Points
- Confirm the commercial launch timeline for the Algovita Spinal Cord Stimulation System in European markets.
- Verify the specific revenue contribution targets associated with the QiG Group subsidiary.
- Assess the competitive landscape for spinal cord stimulation systems in the EU following this approval.